Prime Medicine (PRME) Competitors $4.04 +0.30 (+8.02%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.34 +0.30 (+7.33%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. IDYA, TWST, GLPG, AGIO, BEAM, VCEL, IRON, HRMY, MESO, and CNTAShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include IDEAYA Biosciences (IDYA), Twist Bioscience (TWST), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Beam Therapeutics (BEAM), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors IDEAYA Biosciences Twist Bioscience Galapagos Agios Pharmaceuticals Beam Therapeutics Vericel Disc Medicine Harmony Biosciences Mesoblast Centessa Pharmaceuticals IDEAYA Biosciences (NASDAQ:IDYA) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Do insiders and institutionals believe in IDYA or PRME? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 22.9% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer IDYA or PRME? In the previous week, Prime Medicine had 6 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Prime Medicine and 8 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat Prime Medicine's score of 0.67 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, IDYA or PRME? Prime Medicine has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M303.65-$274.48M-$3.59-6.76Prime Medicine$3.85M141.28-$198.13M-$1.61-2.51 Which has more volatility & risk, IDYA or PRME? IDEAYA Biosciences has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Is IDYA or PRME more profitable? IDEAYA Biosciences' return on equity of -29.28% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -29.28% -27.68% Prime Medicine N/A -107.87%-74.97% Do analysts recommend IDYA or PRME? IDEAYA Biosciences presently has a consensus price target of $48.09, indicating a potential upside of 98.15%. Prime Medicine has a consensus price target of $9.25, indicating a potential upside of 128.96%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.77Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryIDEAYA Biosciences beats Prime Medicine on 8 of the 15 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$503.02M$274.51M$5.55B$20.46BDividend YieldN/AN/A4.74%3.70%P/E Ratio-1.97N/A28.9929.02Price / Sales141.28327.48437.8157.19Price / CashN/A22.4435.0722.46Price / Book2.9510.418.254.43Net Income-$198.13M-$106.40M$3.25B$993.74M7 Day Performance-4.04%-7.56%-3.75%-3.40%1 Month Performance27.85%16.68%2.99%-2.70%1 Year Performance-17.55%6.99%25.34%10.16% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.8683 of 5 stars$4.04+8.0%$9.25+129.0%-17.6%$503.02M$3.85M-1.97234News CoverageInsider TradeGap DownIDYAIDEAYA Biosciences4.1756 of 5 stars$25.02+2.1%$48.09+92.2%-39.5%$2.19B$7M-6.9780Upcoming EarningsGap UpTWSTTwist Bioscience3.5339 of 5 stars$36.53+1.5%$50.40+38.0%-21.6%$2.19B$312.97M-11.24990News CoverageUpcoming EarningsShort Interest ↑Gap DownGLPGGalapagos0.3543 of 5 stars$32.79+0.4%$25.33-22.7%+28.2%$2.16B$275.61M0.001,310AGIOAgios Pharmaceuticals3.5668 of 5 stars$37.20-7.0%$57.33+54.1%-20.4%$2.15B$36.50M3.31390News CoverageEarnings ReportBEAMBeam Therapeutics2.625 of 5 stars$20.83-4.1%$48.75+134.0%-31.4%$2.09B$63.52M-4.52510News CoverageUpcoming EarningsInsider TradeGap DownVCELVericel2.4351 of 5 stars$41.45+3.3%$61.14+47.5%-25.2%$2.09B$237.22M1,382.13300Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionIRONDisc Medicine3.3842 of 5 stars$59.48-1.9%$95.73+60.9%+37.7%$2.06BN/A-15.1730Upcoming EarningsInsider TradeHRMYHarmony Biosciences4.736 of 5 stars$35.76-4.7%$51.00+42.6%+6.2%$2.05B$714.73M13.65200Positive NewsUpcoming EarningsMESOMesoblast0.7684 of 5 stars$15.93-2.6%$18.00+13.0%+140.0%$2.04B$5.67M0.0080CNTACentessa Pharmaceuticals3.1699 of 5 stars$15.20-1.4%$28.10+84.9%+66.9%$2.03B$6.85M-8.40200News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Twist Bioscience Alternatives Galapagos Alternatives Agios Pharmaceuticals Alternatives Beam Therapeutics Alternatives Vericel Alternatives Disc Medicine Alternatives Harmony Biosciences Alternatives Mesoblast Alternatives Centessa Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts